In this section
@article{Long:2024:10.1016/S2213-2600(24)00176-0,
author = {Long, MB and Chotirmall, SH and Shteinberg, M and Chalmers, JD},
doi = {10.1016/S2213-2600(24)00176-0},
journal = {Lancet Respir Med},
pages = {901--914},
title = {Rethinking bronchiectasis as an inflammatory disease.},
url = {http://dx.doi.org/10.1016/S2213-2600(24)00176-0},
volume = {12},
year = {2024}
}
TY - JOUR
AB - Bronchiectasis is understood to be the result of a complex interaction between infection, impaired mucociliary clearance, inflammation, and lung damage. Current therapeutic approaches to bronchiectasis are heavily focused on management of infection along with enhancing mucus clearance. Long-term antibiotics have had limited success in clinical trials, suggesting a need to re-evaluate the concept of bronchiectasis as an infective disorder. We invoke the example of asthma, for which treatment paradigms shifted away from targeting smooth muscle constriction, towards permanently suppressing airway inflammation, reducing risk and ultimately inducing remission with precision anti-inflammatory treatments. In this Review, we argue that bronchiectasis is primarily a chronic inflammatory disease, requiring early identification of at-risk individuals, and we introduce a novel concept of disease activity with important implications for clinical practice and future research. A new generation of novel anti-inflammatory treatments are under development and repurposing of anti-inflammatory agents from other diseases could revolutionise patient care.
AU - Long,MB
AU - Chotirmall,SH
AU - Shteinberg,M
AU - Chalmers,JD
DO - 10.1016/S2213-2600(24)00176-0
EP - 914
PY - 2024///
SP - 901
TI - Rethinking bronchiectasis as an inflammatory disease.
T2 - Lancet Respir Med
UR - http://dx.doi.org/10.1016/S2213-2600(24)00176-0
UR - https://www.ncbi.nlm.nih.gov/pubmed/38971168
VL - 12
ER -
For any enquiries about the Fungal Science Network at Imperial, please contact: